摘要
目的 观察达格列净对2型糖尿病(T2DM)合并心力衰竭患者急性心肌损伤的效果。方法 68例T2DM合并心力衰竭患者分为观察组(36例)和对照组(32例);两组均使用心力衰竭基础治疗,观察组联用达格列净。比较两组心肌损伤标志物和炎症因子水平的变化、主要不良心血管事件(MACE)及心力衰竭复发再住院次数。结果 观察组氨基末端脑钠肽前体、高灵敏肌钙蛋白T、TNF-α、IL-1β、IL-6、C反应蛋白水平及MACE发生率、心力衰竭复发再次住院率明显低于对照组(P<0.01或0.05)。结论 达格列净可减轻T2DM合并心力衰竭患者急性心肌损伤及炎症因子水平,改善心力衰竭。
Objective To observe the effect of dapagliflozin on acute myocardial injury in patients with type 2 diabetes mellitus(T2DM)and heart failure.Methods Sixty-eight patients with T2DM and heart failure were treated with conventional anti-heart failure therapy(n=32,control group)or combined dapagliflozin(n=36,observation group).Myocardial injury markers,inflammatory cytokines,major adverse cardiovascular events(MACE),and rehospitalization of recurrent heart failure were compared between two groups.Results Compared with control group,levels of N-terminal pro-B-type natriuretic peptide(NT-proBNP),high sensitivity cardiac troponin T(Hs-TnT),TNF-α,IL-1β,IL-6,C-reactive protein(CRP),MACE,and rehospitalization of recurrent heart failure were lower in observation group(P<0.01 or 0.05).Conclusion Dapagliflozin can improve acute myocardial injury and inflammatory cytokines in patients with T2DM and heart failure.
作者
李上海
黄春燕
范君宇
梁伟钧
黄瑞娜
LI Shang-hai;HUANG Chun-yan;FAN Jun-yu;LIANG Wei-jun;HUANG Rui-na(Department of Vasculocardiology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524023,China)
出处
《广东医科大学学报》
2024年第1期82-85,共4页
Journal of Guangdong Medical University
基金
湛江市科技计划项目(2022A01187)
湛江市非资助科技攻关计划项目(2021B01026)
广东省医学科研基金项目(A2017494)
广东医科大学青年科研培育基金项目(2001/2XK22007)。
关键词
达格列净
心力衰竭
2型糖尿病
心肌损伤
dapagliflozin
heart failure
type 2 diabetes mellitus
myocardial injury